Higher efficacy of pre-hospital tirofiban with longer pretreatment time to primary PCI: Protection for the negative impact of time delay

EuroIntervention

Volumn 7, Issue 4, 2011, Pages 442-448

  Heestermans, Ton ^a   De Boer, Menko Jan ^b   Van Werkum, Jochem W ^c   Mosterd, Arend ^d   Gosselink, A T Marcel ^b   Dambrink, Jan Henk E ^b   Van Houwelingen, Gert ^e   Koopmans, Petra ^f   Hamm, Christian ^g   Zijlstra, Felix ^h   Ten Berg, Jurriën M ^c   Van 't Hof, Arnoud W J ^b  

^a Northwest Clinics   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f Diagram BV   (Netherlands)

^g KERCKHOFF HEART CENTER   (Germany)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Duration of pre treatment; Glycoprotein IIb IIIa receptor inhibitors; Myocardial infarction; ST segment deviation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO; TIROFIBAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY CARE; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REPERFUSION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY DELAY; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; AMBULANCES; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HEALTH SERVICES ACCESSIBILITY; HEPARIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 80355141658     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I4A73     Document Type: Article

References (17)

1. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr., Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210-247.
2. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
3. van 't Hof AWJ, ten Berg JM, Heestermans T, Dill T, Funck RC, van Werkum JW, Dambrink JHE, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet2008;372:537-546.
4. Heestermans AACM, van Werkum JW, Hamm C, Dill T, Gosselink ATM, de Boer MJ, van Houwelingen G, Hoorntje JCA, Koopmans PC, ten Berg JM, van 't Hof AWJ. Marked reduction of early stent thrombosis with pre-hospital initiation of high dose Tirofiban in ST-segment elevation myocardial infarction: An analysis of the On-TIME 2 trial. J Thromb Haemost 2009;7:1612-1618.
5. van 't Hof AW, Hamm C, Rasoul S, Guptha S, Paolini JF, ten Berg JM, on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention 2007;3:371-380.
6. De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JHE, de Boer MJ, van 't Hof AWJ. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 2005;150:1248-1254. (Pubitemid 41773531)
7. van 't Hof AWJ, Liem AL, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy foracute myocardial infarction. Zwolle Myocardial Infarction Study Group. Lancet 1997;350:615-619. (Pubitemid 27367794)
8. ten Berg JM, van 't Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C; On-TIME 2 Study Group. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010;55:2446-55.
9. Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz HM; National Cardiovascular Data Registry. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 2009;338:b1807. doi: 10.1136/bmj.b1807.
10. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI):randomised trial. Lancet 2006;367:569-578.
11. Zijlstra F, Ernst N, de Boer MJ, Nibbering E, Suryapranata H, Hoorntje JCA, Dambrink JHE, van 't Hof AWJ, Verheugt FW. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002;39:1733-1737. (Pubitemid 34595281)
12. Terkelsen CJ, Nørgaard BL, Lassen JF, Poulsen SH, Gerdes JC, Sloth E, Gøtzsche LB, Rømer FK, Thuesen L, Nielsen TT, Andersen HR. Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study). Eur Heart J 2006;27:267-275. (Pubitemid 43100019)
13. Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol 2004;44:38-43. (Pubitemid 38968453)
14. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall'Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 2009;1:33-43.
15. Hassan AK, Jukema JW, van der Laarse A, Hasan-Ali H, Wolterbeek R, van der Kley F, Spano F, Atsma DE, Schalij MJ. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pre-treatment. EuroIntervention 2009;4:662-668.
16. De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van 't Hof AWJ. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 2008;94:1548-1558.
17. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Eng J Med 2008;358:2205-2217. (Pubitemid 351724450)